Hypertension represents a significant global public health problem, contributing to vascular
and renal morbidity, cardiovascular mortality, and economic burden. For a mostly asymptomatic
disease, there is a huge challenge to maintain a good adherence and longtime persistence of
drug use so as to adequately control it. Even so, a significant proportion of patients will
develop resistant hypertension. In recent years, renal denervation has been argued as an
effective means to address blood pressure problem in several non-Chinese clinical trials. The
technique is to deliver low level radiofrequency energy through the renal artery wall to
target the sympathetic nervous system and then modulate blood pressure.
Shanghai WiseGain Medical Devices Co., LTD has developed the WiseGo Catheter System, which is
an irrigated radiofrequency ablation Catheter. With this Catheter, it is expected to improve
blood pressure status among patients with resistant hypertension failing polypharmacy. The
purpose of this randomized control trial is to obtain an assessment of the efficacy and
safety of WiseGo renal denervation technique in the presence of three standard
antihypertensive medications in Chinese patients.